TLC 3595
Alternative Names: S-723595; TLC-3595Latest Information Update: 15 Nov 2024
Price :
$50 *
At a glance
- Originator Shionogi
- Developer OrsoBio; Shionogi; The Liver Company
- Class Antihyperglycaemics; Hepatoprotectants; Small molecules
- Mechanism of Action Acetyl-CoA carboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 09 Sep 2024 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Type 2 diabetes mellitus presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in Japan (PO)
- 07 Nov 2023 OrsoBio plans a phase IIb in Type 2 diabetes mellitus